Annovis Bio, Inc. (ANVS) fundamentals score
Annovis Bio is a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). It is developing its lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases.
Pharmaceutical Preparations · Healthcare · Listed on NYSE
Overall: 3.6 out of 10, Weak long-term fundamentals
- Growth: 3.5/10
- Profitability: 1.0/10
- Financial health: 7.1/10
- Earnings quality: 5.5/10
- Valuation: 1.5/10
Scores are calculated from Annovis Bio, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10